Biotech

the lobby of Exelixis, Inc., a pharmaceutical company focused on oncology drug discovery and development
General Counsel Brenda Hefti leads legal strategy at Exelixis, launching new oncology treatments and navigating policy challenges

In oncology biotech, legal teams play a central role in advancing scientific innovation within complex regulatory and policy environments. At Exelixis, General Counsel Brenda Hefti, J.D., Ph.D., exemplifies that role by aligning legal strategy with scientific innovation and business objectives. She helps drive the delivery of therapies to patients while guiding the company through litigation, intellectual property strategy, regulatory challenges, and evolving government policy — positioning Exelixis at the critical intersection of law and science.